Boston Scientific, which paid $25m for a 25% stake in the venous stent developer two years ago, has agreed to buy the company in full.

Medical device manufacturer Boston Scientific has agreed to acquire US-based venous stent technology developer and portfolio company Veniti for an initial $108m in cash.

Veniti is developing a venous stent system intended to treat venous disease, a condition where blood stops flowing smoothly to the heart and instead gathers in a patient’s leg veins, by expanding to ensure blocked veins remain open.

The cash payment could be increased by up to $52m in additional payments should the company’s Vici stent…